Hurricane Sandy Rains On User Fee Dates, Advisory Committees
Executive Summary
FDA will extend user fee goal dates as needed to account for the loss of two days in review cycles resulting from the government office shutdown. The extreme weather conditions led to cancellation of three advisory committees during the week of Oct. 29.
You may also be interested in...
Novartis’ Serelaxin Is Early Victim Of East Coast Snow Storm
FDA postpones Feb. 13 advisory committee review of heart failure drug due to “unanticipated weather conditions” expected for the Washington, D.C. area, although the cardio-renal panel’s meeting on The Medicines Co.’s cangrelor will proceed as planned Feb. 12.
GSK’s Breo Ellipta Gets “Snowquestered” As FDA Delays Advisory Cmte
FDA missed its deadline to post the advisory committee briefing materials then postponed the meeting as a winter storm headed towards Washington.
Zogenix’s Stand-alone Hydrocodone To Stand Before Advisory Panel
If approved, Zohydro will be the first extended-release version of hydrocodone and the first not to be combined with other painkillers.